{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ALPMY"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":9.426,"timestamp":1747684800000,"preClose":9.38,"halted":0,"volume":147287,"delay":15,"floatShares":1731101601,"shares":1861787075,"eps":0.074352,"marketStatus":"Pre-Mkt","change":0.046,"latestTime":"05-19 16:00:00 EDT Delay","open":9.12,"high":9.47,"low":9.12,"amount":1385963.2318000004,"amplitude":0.037313,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747747800000},"marketStatusCode":1,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":9.426,"volumeRatio":0.6594973761699627},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","floatShares":1731101601,"roa":"4.21%","roe":"3.26%","lyrEps":0.062841,"volumeRatio":0.6594973761699627,"shares":1861787075,"dividePrice":0.24,"high":9.47,"amplitude":0.037313,"preClose":9.38,"low":9.12,"week52Low":8.37,"pbRate":"1.68","psRate":"1.33","week52High":13.14,"institutionHeld":0,"latestPrice":9.426,"eps":0.074352,"divideRate":0.025461,"volume":147287,"delay":15,"ttmEps":0.074352,"open":9.12,"prevYearClose":9.66,"prevWeekClose":9.38,"prevMonthClose":9.91,"prevQuarterClose":9.66,"fiveDayClose":9.44,"twentyDayClose":9.42,"sixtyDayClose":9.73},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALPMY\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMY\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533907609","title":"Press Release: Notice of Nominees for Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2533907609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533907609?lang=en_us&edition=fundamental","pubTime":"2025-05-07 18:00","pubTimestamp":1746612000,"startTime":"0","endTime":"0","summary":"TOKYO, May 7, 2025 /PRNewswire/ -- Astellas Pharma Inc.  today announced that during a meeting of its Board of Directors held today, it decided a change in Directors as outlined below. The appointment of Andreas Busch and Mark Enyedy as new candidates to be proposed at the 20th Term Annual Shareholders Meeting scheduled for June 19, 2025, represents a significant move in the company's continuous evolution, aimed at enhancing the diverse composition of our Board of Directors. Their extensive experience and insight into the global pharmaceutical industry will further strengthen the board's supervisory function and effectiveness. This decision reflects the voices from stakeholders,  including shareholders. The change is subject to approval at the 20th Term Annual Shareholders Meeting and a subsequent decision at the Board of Directors meeting scheduled for the same day.Kenji Yasukawa       Reelection    Representative Director, Chairman of the. Naoki Okamura        Reelection    Represent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4568","BNTX","BK4535","BK4007","BK4588","ALPMY","BK4139","BK4585","BK4548"],"gpt_icon":0},{"id":"2532607777","title":"Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses","url":"https://stock-news.laohu8.com/highlight/detail?id=2532607777","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532607777?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:00","pubTimestamp":1746104400,"startTime":"0","endTime":"0","summary":"ARVO andRWC abstracts feature analyses on biomarkers, mechanism of disease, patient experience and other data fromIZERVAY pivotal studies. TOKYO, May 1, 2025 /PRNewswire/ -- Astellas Pharma Inc. , maker of IZERVAY, a C5 inhibitor for the treatment of geographic atrophy *, will highlight new data that enhances continued understanding of the science of GA, and the experience of patients living with the progressive disease at the Association for Research in Vision and Ophthalmology Annual Meeting , May 4-8, Salt Lake City, Utah, and Retina World Congress , May 8-11, Fort Lauderdale, Florida.The data comprises nine abstracts, including two oral presentations, featuring analyses on biomarkers, patient experience, mechanism of disease and other insights from the GATHER Phase 3 studies ofIZERVAY for the treatment of GA secondary to age-related macular degeneration .Marci English, Senior Vice President, Biopharma and Ophthalmology Development, Astellas Pharma\"Recognizing the early indicators a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-present-data-geographic-atrophy-130000768.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-present-data-geographic-atrophy-130000768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2098885051.SGD","RWC","LU0823421416.USD","LU2054465674.USD","IE00BMPRXR70.SGD","LU1988902786.USD","BK4529","ALPMY","LU0082616367.USD","LU1989764664.SGD","BK4534","LU2250418816.HKD","BK4141","BK4573","GFS","ALPMF","LU1242518931.SGD","LU0889565833.HKD","LU1303367103.USD","BK4543","LU1803068979.SGD","IE00B5949003.HKD","LU1316542783.SGD","LU1880398554.USD","ACP","IE00BMPRXN33.USD","BK4588","LU1242518857.USD","LU0719512351.SGD","LU1951198990.SGD","BK4512","LU0823421333.USD","LU2458330169.SGD","LU1852331112.SGD","LU1923623000.USD","LU0081259029.USD","BK4575","LU0127658192.USD","LU1951200564.SGD","LU0390134368.USD","IE0009356076.USD","BK4007","LU0198837287.USD","LU2458330243.SGD","LU0109392836.USD","LU2264538146.SGD","BK4614","BK4605","LU0642271901.SGD","IE0004445239.USD"],"gpt_icon":1},{"id":"2531640807","title":"Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531640807","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531640807?lang=en_us&edition=fundamental","pubTime":"2025-04-30 00:00","pubTimestamp":1745942410,"startTime":"0","endTime":"0","summary":"Astellas Pharma Inc.  could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 . This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Astellas Pharma basically reflects positivity about its earnings outlook that could translate into buying pressure and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-pharma-alpmy-upgraded-strong-160010586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMY","ALPMF"],"gpt_icon":0},{"id":"2517980901","title":"Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2517980901","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517980901?lang=en_us&edition=fundamental","pubTime":"2025-03-06 12:02","pubTimestamp":1741233720,"startTime":"0","endTime":"0","summary":"- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions -. TOKYO, March 5, 2025 /PRNewswire/ -- Astellas Pharma Inc.  and YASKAWA Electric Corporation  signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the dual-arm robot \"Maholo.\" In addition, the joint venture will offer platform access to startups and academic institutions, fostering collaboration and innovation in the field of cell therapy.The planned joint venture will leverage Astellas' expertise in R&D and manufacturing for cell therapy and the dual arm robot \"Maholo,\" developed by YASKAWA's subsidiary, Robotic Biology Institute. The closing and establishment of the joint venture company are subject to certain closing conditions, including receipt of required regulatory approvals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/astellas-yaskawa-agree-establish-joint-040200778.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astellas-yaskawa-agree-establish-joint-040200778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALPMY","JYNT","YASKF","YASKY","BK4185","ADC","ALPMF","BK4231","BK4161","BK4080"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-04","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"","actualEps":null},{"date":"2024-08-01","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722499200000,"name":null,"time":"","dateTimestamp":1722484800000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-01","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1698811200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1683172800000}}}